MJALLI, Adnan M.M.,CLARK, Bradley Alan,POLISETTI, Dharma Rao,QUADA, JR.,VALCARCE LOPEZ, Maria Carmen,ANDREWS, Robert Carl,DAVIS, Stephen Thomas,YOKUM, Thomas Scott
申请号：
ES14702159
公开号：
ES2687083T3
申请日:
2014.01.14
申请国别(地区):
ES
年份:
2018
代理人:
摘要：
A combination comprising a Glp1r agonist in combination with Metformin to treat Type 2 diabetes, to decrease the blood glucose of the subjectTo increase the therapeutic efficacy of Metformin to increase therapeutic efficacy of a receptor agonist of the glucagon like peptide 1 (\"The Glp1r agonist\")For Increasing the oral bioavailability of Glp1r agonist, for use in the treatment of a condition selected from the group consisting of: metabolic syndrome, glucose intolerance,Hyperglycemia, dyslipidemia, hypertriglyceridemia, Syndrome X, insulin resistance, impaired glucose tolerance (IGT), obesity, dyslipidemia, diabetes, hyperlipidemia,Arteriosclerosis, atherosclerosis, cardiovascular disease, hypertension, Metabolic Disorders in which the Glp1r agonist is beneficial.Or or complications associated with Diabetes, to try to treat Type 1 diabetes, obesity, to slow gastric emptying, to decrease the levels of GHB CTo increase the glucose dependent insulin secretion, to suppress glucagon secretion to treat eating disorders, or to modulate a Glp1r receptor in humanWhere the Glp1r agonist administered orally is acid and (S) - 3 - (4 - cyano biphenyl - 4-yl) - 2 - [(3R, 7S) - 3 - [4 - (3,4 Dichloro - benziloxi) phenyl] - 1 - methyl - 2 - oxo - 6 - ((S) - 1 - phenyl - propyl) - 2,3,5,6,7,8 - hexahi15 dro - 1H - 4 - 1.6 - oxa anthracene Grabarsky, ITs The Wrong Guy - - 7 - carbonyl] amino} - propionic acid or a pharmaceutically acceptable Salt of the acid, or (S) - 2 - [(3S, 8S) - 3 - [4 - (3,4 - Dichloro - benziloxi) phenyl] - 7 - ((S) - 1 - phenyl - propyl) - 2,3,6,7,8,9 - hexahidro - [1,4] dioxino [2,3] isoquinolino - G - 8 - carbonyl] amino} - 3 - [4 - (2,3 - dimethyl pyridin-4-yl) phenyl] - propionic acid or a pharmaceutically acceptable Salt thereof.Una combinación que comprende un agonista del GLP1R en combinación con metformina para tratar la diabetes tipo 2, para disminuir la glucosa en sangre del sujeto, para aumentar la eficacia terapéutica de la metformina, para aume
